ID   GCH1_HUMAN              Reviewed;         250 AA.
AC   P30793; Q6FHY7; Q9Y4I8;
DT   01-JUL-1993, integrated into UniProtKB/Swiss-Prot.
DT   01-JUL-1993, sequence version 1.
DT   10-MAY-2017, entry version 185.
DE   RecName: Full=GTP cyclohydrolase 1;
DE            EC=3.5.4.16 {ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916, ECO:0000269|PubMed:3753653};
DE   AltName: Full=GTP cyclohydrolase I;
DE            Short=GTP-CH-I;
GN   Name=GCH1; Synonyms=DYT5, GCH;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GCH-1; GCH-2 AND GCH-3).
RC   TISSUE=Liver;
RX   PubMed=1520321; DOI=10.1016/S0006-291X(05)81501-3;
RA   Togari A., Ichinose H., Matsumoto S., Fujita K., Nagatsu T.;
RT   "Multiple mRNA forms of human GTP cyclohydrolase I.";
RL   Biochem. Biophys. Res. Commun. 187:359-365(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GCH-1 AND GCH-2), AND FUNCTION.
RC   TISSUE=Liver;
RX   PubMed=8068008; DOI=10.1042/bj3020215;
RA   Guetlich M., Jaeger E., Rucknaegel K.P., Werner T., Roedl W.,
RA   Ziegler I., Bacher A.;
RT   "Human GTP cyclohydrolase I: only one out of three cDNA isoforms gives
RT   rise to the active enzyme.";
RL   Biochem. J. 302:215-221(1994).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   TISSUE=Pheochromocytoma;
RX   PubMed=8695054; DOI=10.1007/BF01271561;
RA   Nomura T., Ohtsuki M., Matsui S., Sumi-Ichinose C., Nomura H.,
RA   Hagino Y., Iwase K., Ichinose H., Fujita K., Nagatsu T.;
RT   "Isolation of a full-length cDNA clone for human GTP cyclohydrolase I
RT   type 1 from pheochromocytoma.";
RL   J. Neural Transm. 101:237-242(1995).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS GCH-1 AND GCH-4).
RC   TISSUE=Myelomonocyte;
RX   PubMed=11284739; DOI=10.1042/0264-6021:3550499;
RA   Golderer G., Werner E.R., Heufler C., Strohmaier W., Grobner P.,
RA   Werner-Felmayer G.;
RT   "GTP cyclohydrolase I mRNA: novel splice variants in the slime mould
RT   Physarum polycephalum and in human monocytes (THP-1) indicate
RT   conservation of mRNA processing.";
RL   Biochem. J. 355:499-507(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GCH-1).
RA   Ebert L., Schick M., Neubert P., Schatten R., Henze S., Korn B.;
RT   "Cloning of human full open reading frames in Gateway(TM) system entry
RT   vector (pDONR201).";
RL   Submitted (JUN-2004) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM GCH-1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-114.
RC   TISSUE=Granulocyte;
RX   PubMed=8666288; DOI=10.1016/0378-1119(95)00886-1;
RA   Witter K., Werner T., Blusch J.H., Schneider E.-M., Riess O.,
RA   Ziegler I., Roedl W., Bacher A., Guetlich M.;
RT   "Cloning, sequencing and functional studies of the gene encoding human
RT   GTP cyclohydrolase I.";
RL   Gene 171:285-290(1996).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 60-242.
RX   PubMed=1482676;
RA   Guetlich M., Schott K., Werner T., Bacher A., Ziegler I.;
RT   "Species and tissue specificity of mammalian GTP cyclohydrolase I
RT   messenger RNA.";
RL   Biochim. Biophys. Acta 1171:133-140(1992).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 116-209.
RX   PubMed=7730309; DOI=10.1074/jbc.270.17.10062;
RA   Ichinose H., Ohye T., Matsuda Y., Hori T.A., Blau N., Burlina A.,
RA   Rouse B., Matalon R., Fujita K., Nagatsu T.;
RT   "Characterization of mouse and human GTP cyclohydrolase I genes.
RT   Mutations in patients with GTP cyclohydrolase I deficiency.";
RL   J. Biol. Chem. 270:10062-10071(1995).
RN   [11]
RP   ENZYME ACTIVITY, AND ENZYME REGULATION.
RX   PubMed=3753653; DOI=10.1016/0304-4165(86)90115-7;
RA   Blau N., Niederwieser A.;
RT   "The application of 8-aminoguanosine triphosphate, a new inhibitor of
RT   GTP cyclohydrolase I, to the purification of the enzyme from human
RT   liver.";
RL   Biochim. Biophys. Acta 880:26-31(1986).
RN   [12]
RP   BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=2500984; DOI=10.1016/0300-9084(89)90006-0;
RA   Shen R.-S., Alam A., Zhang Y.X.;
RT   "Human liver GTP cyclohydrolase I: purification and some properties.";
RL   Biochimie 71:343-349(1989).
RN   [13]
RP   ENZYME ACTIVITY, AND SUBCELLULAR LOCATION.
RX   PubMed=2463916; DOI=10.1111/j.1432-1033.1989.tb14491.x;
RA   Schoedon G., Redweik U., Curtius H.-C.;
RT   "Purification of GTP cyclohydrolase I from human liver and production
RT   of specific monoclonal antibodies.";
RL   Eur. J. Biochem. 178:627-634(1989).
RN   [14]
RP   INDUCTION.
RX   PubMed=7678411;
RA   Werner-Felmayer G., Werner E.R., Fuchs D., Hausen A., Reibnegger G.,
RA   Schmidt K., Weiss G., Wachter H.;
RT   "Pteridine biosynthesis in human endothelial cells. Impact on nitric
RT   oxide-mediated formation of cyclic GMP.";
RL   J. Biol. Chem. 268:1842-1846(1993).
RN   [15]
RP   REVIEW ON VARIANTS.
RX   PubMed=9222755;
RX   DOI=10.1002/(SICI)1098-1004(1997)10:1<11::AID-HUMU2>3.0.CO;2-P;
RA   Thoeny B., Blau N.;
RT   "Mutations in the GTP cyclohydrolase I and 6-pyruvoyl-tetrahydropterin
RT   synthase genes.";
RL   Hum. Mutat. 10:11-20(1997).
RN   [16]
RP   FUNCTION, AND INDUCTION.
RX   PubMed=9445252; DOI=10.1161/01.ATV.18.1.27;
RA   Katusic Z.S., Stelter A., Milstien S.;
RT   "Cytokines stimulate GTP cyclohydrolase I gene expression in cultured
RT   human umbilical vein endothelial cells.";
RL   Arterioscler. Thromb. Vasc. Biol. 18:27-32(1998).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=12176133; DOI=10.1016/S0008-6363(02)00460-1;
RA   Cai S., Alp N.J., McDonald D., Smith I., Kay J., Canevari L.,
RA   Heales S., Channon K.M.;
RT   "GTP cyclohydrolase I gene transfer augments intracellular
RT   tetrahydrobiopterin in human endothelial cells: effects on nitric
RT   oxide synthase activity, protein levels and dimerisation.";
RL   Cardiovasc. Res. 55:838-849(2002).
RN   [18]
RP   INDUCTION.
RX   PubMed=12002810; DOI=10.1016/S0024-3205(02)01503-5;
RA   Ohtsuki M., Shiraishi H., Kato T., Kuroda R., Tazawa M.,
RA   Sumi-Ichinose C., Tada S., Udagawa Y., Itoh M., Hishida H.,
RA   Ichinose H., Nagatsu T., Hagino Y., Nomura T.;
RT   "cAMP inhibits cytokine-induced biosynthesis of tetrahydrobiopterin in
RT   human umbilical vein endothelial cells.";
RL   Life Sci. 70:2187-2198(2002).
RN   [19]
RP   INDUCTION.
RX   PubMed=12607127; DOI=10.1007/s00395-003-0394-y;
RA   Gesierich A., Niroomand F., Tiefenbacher C.P.;
RT   "Role of human GTP cyclohydrolase I and its regulatory protein in
RT   tetrahydrobiopterin metabolism.";
RL   Basic Res. Cardiol. 98:69-75(2003).
RN   [20]
RP   INDUCTION.
RX   PubMed=14646243; DOI=10.1254/jphs.93.265;
RA   Shiraishi H., Kato T., Atsuta K., Sumi-Ichinose C., Ohtsuki M.,
RA   Itoh M., Hishida H., Tada S., Udagawa Y., Nagatsu T., Hagino Y.,
RA   Ichinose H., Nomura T.;
RT   "cGMP inhibits GTP cyclohydrolase I activity and biosynthesis of
RT   tetrahydrobiopterin in human umbilical vein endothelial cells.";
RL   J. Pharmacol. Sci. 93:265-271(2003).
RN   [21]
RP   ENZYME REGULATION.
RX   PubMed=14717702; DOI=10.1046/j.1432-1033.2003.03933.x;
RA   Suzuki T., Kurita H., Ichinose H.;
RT   "GTP cyclohydrolase I utilizes metal-free GTP as its substrate.";
RL   Eur. J. Biochem. 271:349-355(2004).
RN   [22]
RP   FUNCTION.
RX   PubMed=16338639; DOI=10.1016/j.brainresprot.2005.10.005;
RA   Duan C.-L., Su Y., Zhao C.-L., Lu L.-L., Xu Q.-Y., Yang H.;
RT   "The assays of activities and function of TH, AADC, and GCH1 and their
RT   potential use in ex vivo gene therapy of PD.";
RL   Brain Res. Brain Res. Protoc. 16:37-43(2005).
RN   [23]
RP   INDUCTION.
RX   PubMed=15604419; DOI=10.1161/01.RES.0000153669.24827.DF;
RA   Huang A., Zhang Y.-Y., Chen K., Hatakeyama K., Keaney J.F. Jr.;
RT   "Cytokine-stimulated GTP cyclohydrolase I expression in endothelial
RT   cells requires coordinated activation of nuclear factor-kappaB and
RT   Stat1/Stat3.";
RL   Circ. Res. 96:164-171(2005).
RN   [24]
RP   INDUCTION.
RX   PubMed=15649650; DOI=10.1016/j.freeradbiomed.2004.11.004;
RA   Kalivendi S., Hatakeyama K., Whitsett J., Konorev E., Kalyanaraman B.,
RA   Vasquez-Vivar J.;
RT   "Changes in tetrahydrobiopterin levels in endothelial cells and adult
RT   cardiomyocytes induced by LPS and hydrogen peroxide -- a role for
RT   GFRP?";
RL   Free Radic. Biol. Med. 38:481-491(2005).
RN   [25]
RP   SUBUNIT.
RX   PubMed=16848765; DOI=10.1042/BJ20060765;
RA   Pandya M.J., Golderer G., Werner E.R., Werner-Felmayer G.;
RT   "Interaction of human GTP cyclohydrolase I with its splice variants.";
RL   Biochem. J. 400:75-80(2006).
RN   [26]
RP   ENZYME ACTIVITY, ENZYME REGULATION, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=16778797; DOI=10.1038/sj.jid.5700425;
RA   Chavan B., Gillbro J.M., Rokos H., Schallreuter K.U.;
RT   "GTP cyclohydrolase feedback regulatory protein controls cofactor 6-
RT   tetrahydrobiopterin synthesis in the cytosol and in the nucleus of
RT   epidermal keratinocytes and melanocytes.";
RL   J. Invest. Dermatol. 126:2481-2489(2006).
RN   [27]
RP   INTERACTION WITH AHSA1 AND GCHFR.
RX   PubMed=16696853; DOI=10.1111/j.1471-4159.2006.03836.x;
RA   Swick L., Kapatos G.;
RT   "A yeast 2-hybrid analysis of human GTP cyclohydrolase I protein
RT   interactions.";
RL   J. Neurochem. 97:1447-1455(2006).
RN   [28]
RP   FUNCTION.
RX   PubMed=17057711; DOI=10.1038/nm1490;
RA   Tegeder I., Costigan M., Griffin R.S., Abele A., Belfer I.,
RA   Schmidt H., Ehnert C., Nejim J., Marian C., Scholz J., Wu T.,
RA   Allchorne A., Diatchenko L., Binshtok A.M., Goldman D., Adolph J.,
RA   Sama S., Atlas S.J., Carlezon W.A., Parsegian A., Loetsch J.,
RA   Fillingim R.B., Maixner W., Geisslinger G., Max M.B., Woolf C.J.;
RT   "GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity
RT   and persistence.";
RL   Nat. Med. 12:1269-1277(2006).
RN   [29]
RP   PHOSPHORYLATION AT SER-81.
RX   PubMed=17704208; DOI=10.1161/CIRCRESAHA.107.153809;
RA   Widder J.D., Chen W., Li L., Dikalov S., Thony B., Hatakeyama K.,
RA   Harrison D.G.;
RT   "Regulation of tetrahydrobiopterin biosynthesis by shear stress.";
RL   Circ. Res. 101:830-838(2007).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (3.1 ANGSTROMS) OF 55-250, SUBUNIT, AND
RP   ZINC-BINDING SITES.
RX   PubMed=11087827; DOI=10.1073/pnas.240463497;
RA   Auerbach G., Herrmann A., Bracher A., Bader G., Gutlich M.,
RA   Fischer M., Neukamm M., Garrido-Franco M., Richardson J., Nar H.,
RA   Huber R., Bacher A.;
RT   "Zinc plays a key role in human and bacterial GTP cyclohydrolase I.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:13567-13572(2000).
RN   [32]
RP   VARIANTS DRD TRP-88; VAL-134 AND GLU-201.
RX   PubMed=7874165; DOI=10.1038/ng1194-236;
RA   Ichinose H., Ohye T., Takahashi E., Seki N., Hori T., Segawa M.,
RA   Nomura Y., Endo K., Tanaka H., Tsuji S., Fujita K., Nagatsu T.;
RT   "Hereditary progressive dystonia with marked diurnal fluctuation
RT   caused by mutations in the GTP cyclohydrolase I gene.";
RL   Nat. Genet. 8:236-242(1994).
RN   [33]
RP   VARIANT DRD PRO-79, AND VARIANTS HPABH4B HIS-184 AND ILE-211.
RX   PubMed=7501255; DOI=10.1016/0304-3940(95)11820-M;
RA   Ichinose H., Ohye T., Segawa M., Nomura Y., Endo K., Tanaka H.,
RA   Tsuji S., Fujita K., Nagatsu T.;
RT   "GTP cyclohydrolase I gene in hereditary progressive dystonia with
RT   marked diurnal fluctuation.";
RL   Neurosci. Lett. 196:5-8(1995).
RN   [34]
RP   VARIANT DRD PRO-144.
RX   PubMed=8957022; DOI=10.1002/ana.410400517;
RA   Hirano M., Tamaru Y., Ito H., Matsumoto S., Imai T., Ueno S.;
RT   "Mutant GTP cyclohydrolase I mRNA levels contribute to dopa-responsive
RT   dystonia onset.";
RL   Ann. Neurol. 40:796-798(1996).
RN   [35]
RP   VARIANTS DRD PRO-88; PRO-153; ARG-203; ARG-224 AND SER-234.
RX   PubMed=8852666; DOI=10.1093/hmg/5.3.403;
RA   Bandmann O., Nygaard T.G., Surtess R., Mardsen C.D., Wood N.W.,
RA   Harding A.E.;
RT   "Dopa-responsive dystonia in British patients: new mutations of the
RT   GTP-cyclohydrolase I gene and evidence for genetic heterogeneity.";
RL   Hum. Mol. Genet. 5:403-406(1996).
RN   [36]
RP   VARIANT DRD SER-178.
RX   PubMed=9120469; DOI=10.1136/jnnp.62.4.420;
RA   Beyer K., Lao-Villadoniga J.I., Vecino-Bilbao B., Cacabelos R.,
RA   de la Fuent-Fernandez R.;
RT   "A novel point mutation in the GTP cyclohydrolase I gene in a Spanish
RT   family with hereditary progressive and dopa responsive dystonia.";
RL   J. Neurol. Neurosurg. Psych. 62:420-421(1997).
RN   [37]
RP   VARIANTS DRD LEU-23 AND ASN-115.
RX   PubMed=9328244; DOI=10.1136/jnnp.63.3.304;
RA   Jarman P.R., Bandmann O., Marsden C.D., Wood N.W.;
RT   "GTP cyclohydrolase I mutations in patients with dystonia responsive
RT   to anticholinergic drugs.";
RL   J. Neurol. Neurosurg. Psych. 63:304-308(1997).
RN   [38]
RP   VARIANTS HPABH4B ASP-108; THR-221 AND ARG-224.
RX   PubMed=9667588; DOI=10.1002/ana.410440107;
RA   Furukawa Y., Kish S.J., Bebin E.M., Jacobson R.D., Fryburg J.S.,
RA   Wilson W.G., Shimadzu M., Hyland K., Trugman J.M.;
RT   "Dystonia with motor delay in compound heterozygotes for GTP-
RT   cyclohydrolase I gene mutations.";
RL   Ann. Neurol. 44:10-16(1998).
RN   [39]
RP   VARIANTS DRD GLN-71; VAL-74; ALA-83; ILE-191; VAL-211 AND TRP-241.
RX   PubMed=9778264; DOI=10.1002/ana.410440411;
RA   Bandmann O., Valente E.M., Holmans P., Surtees R.A., Walters J.H.,
RA   Wevers R.A., Marsden C.D., Wood N.W.;
RT   "Dopa-responsive dystonia: a clinical and molecular genetic study.";
RL   Ann. Neurol. 44:649-656(1998).
RN   [40]
RP   VARIANT DRD SER-249.
RX   PubMed=10987649; DOI=10.1007/s004390051093;
RA   Hwu W.-L., Wang P.-J., Hsiao K.-J., Wang T.-R., Chiou Y.-W.,
RA   Lee Y.-M.;
RT   "Dopa-responsive dystonia induced by a recessive GTP cyclohydrolase I
RT   mutation.";
RL   Hum. Genet. 105:226-230(1999).
RN   [41]
RP   VARIANTS DRD ARG-102; LYS-102; ARG-141; TRP-141; THR-176; SER-178 AND
RP   LYS-186.
RX   PubMed=10582612; DOI=10.1046/j.1471-4159.1999.0732510.x;
RA   Suzuki T., Ohye T., Inagaki H., Nagatsu T., Ichinose H.;
RT   "Characterization of wild-type and mutants of recombinant human GTP
RT   cyclohydrolase I: relationship to etiology of dopa-responsive
RT   dystonia.";
RL   J. Neurochem. 73:2510-2516(1999).
RN   [42]
RP   VARIANT DRD LYS-135.
RX   PubMed=10208576; DOI=10.1097/00001756-199902250-00008;
RA   Brique S., Destee A., Lambert J.-C., Mouroux V., Delacourte A.,
RA   Amouyel P., Chartier-Harlin M.-C.;
RT   "A new GTP-cyclohydrolase I mutation in an unusual dopa-responsive
RT   dystonia, familial form.";
RL   NeuroReport 10:487-491(1999).
RN   [43]
RP   VARIANT DRD VAL-90.
RX   PubMed=10076897; DOI=10.1016/S0304-3940(98)00984-7;
RA   Hirano M., Komure O., Ueno S.;
RT   "A novel missense mutant inactivates GTP cyclohydrolase I in dopa-
RT   responsive dystonia.";
RL   Neurosci. Lett. 260:181-184(1999).
RN   [44]
RP   VARIANTS DRD ALA-83; 88-ARG-GLN-89 DEL; SER-178; ARG-180; LEU-199 AND
RP   GLU-201.
RX   PubMed=10825351; DOI=10.1093/brain/123.6.1112;
RA   Tassin J., Duerr A., Bonnet A.-M., Gil R., Vidailhet M.,
RA   Luecking C.B., Goas J.-Y., Durif F., Abada M., Echenne B., Motte J.,
RA   Lagueny A., Lacomblez L., Jedynak P., Bartholome B., Agid Y.,
RA   Brice A.;
RT   "Levodopa-responsive dystonia. GTP cyclohydrolase I or parkin
RT   mutations?";
RL   Brain 123:1112-1121(2000).
RN   [45]
RP   VARIANTS DRD ARG-163 AND VAL-213.
RX   PubMed=11113234; DOI=10.1212/WNL.55.11.1735;
RA   Steinberger D., Korinthenberg R., Topka H., Berghaeuser M., Wedde R.,
RA   Mueller U.;
RT   "Dopa-responsive dystonia: mutation analysis of GCH1 and analysis of
RT   therapeutic doses of L-dopa. German Dystonia Study Group.";
RL   Neurology 55:1735-1737(2000).
RN   [46]
RP   VARIANT DRD ARG-224.
RX   PubMed=12391354; DOI=10.1212/WNL.59.8.1241;
RA   Leuzzi V., Carducci C., Carducci C., Cardona F., Artiola C.,
RA   Antonozzi I.;
RT   "Autosomal dominant GTP-CH deficiency presenting as a dopa-responsive
RT   myoclonus-dystonia syndrome.";
RL   Neurology 59:1241-1243(2002).
RN   [47]
RP   VARIANT DRD ILE-106.
RX   PubMed=17101830; DOI=10.1001/archneur.63.11.1605;
RA   Ohta E., Funayama M., Ichinose H., Toyoshima I., Urano F., Matsuo M.,
RA   Tomoko N., Yukihiko K., Yoshino S., Yokoyama H., Shimazu H., Maeda K.,
RA   Hasegawa K., Obata F.;
RT   "Novel mutations in the guanosine triphosphate cyclohydrolase 1 gene
RT   associated with DYT5 dystonia.";
RL   Arch. Neurol. 63:1605-1610(2006).
RN   [48]
RP   VARIANTS CYS-75; VAL-98 AND THR-135.
RX   PubMed=23762320; DOI=10.1371/journal.pone.0065215;
RA   Cai C., Shi W., Zeng Z., Zhang M., Ling C., Chen L., Cai C., Zhang B.,
RA   Li W.D.;
RT   "GTP cyclohydrolase I and tyrosine hydroxylase gene mutations in
RT   familial and sporadic dopa-responsive dystonia patients.";
RL   PLoS ONE 8:E65215-E65215(2013).
CC   -!- FUNCTION: Positively regulates nitric oxide synthesis in umbilical
CC       vein endothelial cells (HUVECs). May be involved in dopamine
CC       synthesis. May modify pain sensitivity and persistence. Isoform
CC       GCH-1 is the functional enzyme, the potential function of the
CC       enzymatically inactive isoforms remains unknown.
CC       {ECO:0000269|PubMed:12176133, ECO:0000269|PubMed:16338639,
CC       ECO:0000269|PubMed:17057711, ECO:0000269|PubMed:8068008,
CC       ECO:0000269|PubMed:9445252}.
CC   -!- CATALYTIC ACTIVITY: GTP + H(2)O = formate + 2-amino-4-hydroxy-6-
CC       (erythro-1,2,3-trihydroxypropyl)-dihydropteridine triphosphate.
CC       {ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916,
CC       ECO:0000269|PubMed:3753653}.
CC   -!- ENZYME REGULATION: GTP shows a positive allosteric effect, and
CC       tetrahydrobiopterin inhibits the enzyme activity. Zinc is required
CC       for catalytic activity. Inhibited by Mg(2+).
CC       {ECO:0000269|PubMed:14717702, ECO:0000269|PubMed:16778797,
CC       ECO:0000269|PubMed:3753653}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=116 uM for GTP {ECO:0000269|PubMed:2500984};
CC       pH dependence:
CC         Optimum pH is 7.7 in phosphate buffer.
CC         {ECO:0000269|PubMed:2500984};
CC       Temperature dependence:
CC         Relatively stable at high temperatures. Retains 50% of its
CC         activity after incubation at 70 degrees Celsius for 15 minutes.
CC         {ECO:0000269|PubMed:2500984};
CC   -!- PATHWAY: Cofactor biosynthesis; 7,8-dihydroneopterin triphosphate
CC       biosynthesis; 7,8-dihydroneopterin triphosphate from GTP: step
CC       1/1. {ECO:0000305|PubMed:16778797, ECO:0000305|PubMed:2463916,
CC       ECO:0000305|PubMed:3753653}.
CC   -!- SUBUNIT: Toroid-shaped homodecamer, composed of a dimer of
CC       pentamers. The inactive isoforms also form decamers and may
CC       possibly be incorporated into GCH1 heterodecamers, decreasing
CC       enzyme stability and activity. Interacts with AHSA1 and
CC       GCHFR/GFRP. {ECO:0000269|PubMed:11087827,
CC       ECO:0000269|PubMed:16696853, ECO:0000269|PubMed:16848765}.
CC   -!- INTERACTION:
CC       O95433:AHSA1; NbExp=3; IntAct=EBI-958183, EBI-448610;
CC       P63104:YWHAZ; NbExp=4; IntAct=EBI-958183, EBI-347088;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:12176133,
CC       ECO:0000269|PubMed:16778797, ECO:0000269|PubMed:2463916}. Nucleus
CC       {ECO:0000269|PubMed:16778797}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=GCH-1;
CC         IsoId=P30793-1; Sequence=Displayed;
CC       Name=GCH-2;
CC         IsoId=P30793-2; Sequence=VSP_001612, VSP_001613;
CC       Name=GCH-3;
CC         IsoId=P30793-3; Sequence=VSP_001610;
CC       Name=GCH-4;
CC         IsoId=P30793-4; Sequence=VSP_001611, VSP_001614;
CC   -!- TISSUE SPECIFICITY: In epidermis, expressed predominantly in basal
CC       undifferentiated keratinocytes and in some but not all melanocytes
CC       (at protein level). {ECO:0000269|PubMed:16778797}.
CC   -!- INDUCTION: Up-regulated by IFNG/IFN-gamma, TNF, IL1B/interleukin-1
CC       beta, bacterial lipopolysaccharides (LPS) and phenylalanine, and
CC       down-regulated by dibutyryl-cAMP, iloprost and 8-bromo-cGMP in
CC       HUVEC cells. Up-regulation of GCH1 expression, in turn, stimulates
CC       production of tetrahydrobiopterin, with subsequent elevation of
CC       endothelial nitric oxide synthase activity. Cytokine-induced GCH1
CC       up-regulation in HUVECs in response to TNF and IFNG/IFN-gamma
CC       involves cooperative activation of both the NF-kappa-B and
CC       JAK2/STAT pathways. Also up-regulated by hydrogen peroxide in
CC       human aorta endothelial cells (HAECs).
CC       {ECO:0000269|PubMed:12002810, ECO:0000269|PubMed:12607127,
CC       ECO:0000269|PubMed:14646243, ECO:0000269|PubMed:15604419,
CC       ECO:0000269|PubMed:15649650, ECO:0000269|PubMed:7678411,
CC       ECO:0000269|PubMed:9445252}.
CC   -!- PTM: Phosphorylated by casein kinase II at Ser-81 in HAECs during
CC       oscillatory shear stress; phosphorylation at Ser-81 results in
CC       increased enzyme activity. {ECO:0000269|PubMed:17704208}.
CC   -!- DISEASE: Hyperphenylalaninemia, BH4-deficient, B (HPABH4B)
CC       [MIM:233910]: A disease characterized by malignant
CC       hyperphenylalaninemia due to tetrahydrobiopterin deficiency, and
CC       defective neurotransmission due to depletion of the
CC       neurotransmitters dopamine and serotonin. The principal symptoms
CC       include: psychomotor retardation, tonicity disorders, convulsions,
CC       drowsiness, irritability, abnormal movements, hyperthermia,
CC       hypersalivation, and difficulty swallowing. Some patients may
CC       present a phenotype of intermediate severity between severe
CC       hyperphenylalaninemia and mild dystonia. In this intermediate
CC       phenotype, there is marked motor delay, but no mental retardation
CC       and only minimal, if any, hyperphenylalaninemia.
CC       {ECO:0000269|PubMed:7501255, ECO:0000269|PubMed:9667588}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Dystonia, dopa-responsive (DRD) [MIM:128230]: A form of
CC       dystonia that responds to L-DOPA treatment without side effects.
CC       Dystonia is defined by the presence of sustained involuntary
CC       muscle contractions, often leading to abnormal postures. DRD
CC       typically presents in childhood with walking problems due to
CC       dystonia of the lower limbs and worsening of the dystonia towards
CC       the evening. It is characterized by postural and motor
CC       disturbances showing marked diurnal fluctuation. Torsion of the
CC       trunk is unusual. Symptoms are alleviated after sleep and
CC       aggravated by fatigue and exercise. {ECO:0000269|PubMed:10076897,
CC       ECO:0000269|PubMed:10208576, ECO:0000269|PubMed:10582612,
CC       ECO:0000269|PubMed:10825351, ECO:0000269|PubMed:10987649,
CC       ECO:0000269|PubMed:11113234, ECO:0000269|PubMed:12391354,
CC       ECO:0000269|PubMed:17101830, ECO:0000269|PubMed:7501255,
CC       ECO:0000269|PubMed:7874165, ECO:0000269|PubMed:8852666,
CC       ECO:0000269|PubMed:8957022, ECO:0000269|PubMed:9120469,
CC       ECO:0000269|PubMed:9328244, ECO:0000269|PubMed:9778264}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- SIMILARITY: Belongs to the GTP cyclohydrolase I family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; S44049; AAB23164.1; -; mRNA.
DR   EMBL; S44053; AAB23165.1; -; mRNA.
DR   EMBL; S43856; AAB23166.1; -; mRNA.
DR   EMBL; Z29433; CAB77391.1; -; mRNA.
DR   EMBL; Z29434; CAB77392.1; -; mRNA.
DR   EMBL; U19523; AAB16861.1; -; mRNA.
DR   EMBL; U66095; AAD38866.1; -; mRNA.
DR   EMBL; U66097; AAD38868.1; -; mRNA.
DR   EMBL; CR536551; CAG38788.1; -; mRNA.
DR   EMBL; CH471061; EAW80647.1; -; Genomic_DNA.
DR   EMBL; BC025415; AAH25415.1; -; mRNA.
DR   EMBL; L29478; AAB42186.1; -; Genomic_DNA.
DR   EMBL; Z30952; CAA83213.1; -; Genomic_DNA.
DR   EMBL; Z16418; CAA78908.1; -; mRNA.
DR   EMBL; U19259; AAB60633.1; -; Genomic_DNA.
DR   EMBL; U19256; AAB60633.1; JOINED; Genomic_DNA.
DR   EMBL; U19257; AAB60633.1; JOINED; Genomic_DNA.
DR   EMBL; U19258; AAB60633.1; JOINED; Genomic_DNA.
DR   CCDS; CCDS41954.1; -. [P30793-4]
DR   CCDS; CCDS45110.1; -. [P30793-2]
DR   CCDS; CCDS9720.1; -. [P30793-1]
DR   PIR; G01630; PC1117.
DR   PIR; JC1225; JC1225.
DR   RefSeq; NP_000152.1; NM_000161.2. [P30793-1]
DR   RefSeq; NP_001019195.1; NM_001024024.1. [P30793-1]
DR   RefSeq; NP_001019241.1; NM_001024070.1. [P30793-4]
DR   RefSeq; NP_001019242.1; NM_001024071.1. [P30793-2]
DR   UniGene; Hs.86724; -.
DR   PDB; 1FB1; X-ray; 3.10 A; A/B/C/D/E=55-250.
DR   PDBsum; 1FB1; -.
DR   ProteinModelPortal; P30793; -.
DR   SMR; P30793; -.
DR   BioGrid; 108913; 30.
DR   IntAct; P30793; 14.
DR   MINT; MINT-3011998; -.
DR   STRING; 9606.ENSP00000378890; -.
DR   DrugBank; DB02377; Guanine.
DR   DrugBank; DB02325; Isopropyl Alcohol.
DR   iPTMnet; P30793; -.
DR   PhosphoSitePlus; P30793; -.
DR   BioMuta; GCH1; -.
DR   DMDM; 399536; -.
DR   EPD; P30793; -.
DR   MaxQB; P30793; -.
DR   PaxDb; P30793; -.
DR   PeptideAtlas; P30793; -.
DR   PRIDE; P30793; -.
DR   DNASU; 2643; -.
DR   Ensembl; ENST00000395514; ENSP00000378890; ENSG00000131979. [P30793-1]
DR   Ensembl; ENST00000491895; ENSP00000419045; ENSG00000131979. [P30793-1]
DR   Ensembl; ENST00000536224; ENSP00000445246; ENSG00000131979. [P30793-2]
DR   Ensembl; ENST00000543643; ENSP00000444011; ENSG00000131979. [P30793-4]
DR   Ensembl; ENST00000622544; ENSP00000477796; ENSG00000131979. [P30793-1]
DR   GeneID; 2643; -.
DR   KEGG; hsa:2643; -.
DR   UCSC; uc001xbh.2; human. [P30793-1]
DR   CTD; 2643; -.
DR   DisGeNET; 2643; -.
DR   GeneCards; GCH1; -.
DR   GeneReviews; GCH1; -.
DR   HGNC; HGNC:4193; GCH1.
DR   HPA; HPA028612; -.
DR   MalaCards; GCH1; -.
DR   MIM; 128230; phenotype.
DR   MIM; 233910; phenotype.
DR   MIM; 600225; gene.
DR   neXtProt; NX_P30793; -.
DR   OpenTargets; ENSG00000131979; -.
DR   Orphanet; 98808; Autosomal dominant dopa-responsive dystonia.
DR   Orphanet; 2102; GTP cyclohydrolase I deficiency.
DR   PharmGKB; PA28608; -.
DR   eggNOG; KOG2698; Eukaryota.
DR   eggNOG; COG0302; LUCA.
DR   GeneTree; ENSGT00390000013481; -.
DR   HOGENOM; HOG000221222; -.
DR   HOVERGEN; HBG003136; -.
DR   InParanoid; P30793; -.
DR   KO; K01495; -.
DR   OMA; MGKVHIG; -.
DR   OrthoDB; EOG091G0PCE; -.
DR   PhylomeDB; P30793; -.
DR   TreeFam; TF105616; -.
DR   BioCyc; MetaCyc:HS05586-MONOMER; -.
DR   BRENDA; 3.5.4.16; 2681.
DR   Reactome; R-HSA-1474151; Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation.
DR   SABIO-RK; P30793; -.
DR   UniPathway; UPA00848; UER00151.
DR   ChiTaRS; GCH1; human.
DR   EvolutionaryTrace; P30793; -.
DR   GeneWiki; GTP_cyclohydrolase_I; -.
DR   GenomeRNAi; 2643; -.
DR   PRO; PR:P30793; -.
DR   Proteomes; UP000005640; Chromosome 14.
DR   Bgee; ENSG00000131979; -.
DR   CleanEx; HS_GCH1; -.
DR   ExpressionAtlas; P30793; baseline and differential.
DR   Genevisible; P30793; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0044306; C:neuron projection terminus; TAS:ParkinsonsUK-UCL.
DR   GO; GO:0031965; C:nuclear membrane; IDA:HPA.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0043234; C:protein complex; IDA:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IEA:Ensembl.
DR   GO; GO:0050662; F:coenzyme binding; IEA:Ensembl.
DR   GO; GO:0005525; F:GTP binding; IDA:UniProtKB.
DR   GO; GO:0003934; F:GTP cyclohydrolase I activity; IDA:UniProtKB.
DR   GO; GO:0030742; F:GTP-dependent protein binding; IEA:Ensembl.
DR   GO; GO:0003924; F:GTPase activity; IDA:UniProtKB.
DR   GO; GO:0051019; F:mitogen-activated protein kinase binding; IPI:ParkinsonsUK-UCL.
DR   GO; GO:0042803; F:protein homodimerization activity; IPI:UniProtKB.
DR   GO; GO:0031369; F:translation initiation factor binding; IEA:Ensembl.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0035998; P:7,8-dihydroneopterin 3'-triphosphate biosynthetic process; IEA:UniProtKB-UniPathway.
DR   GO; GO:0042416; P:dopamine biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0045776; P:negative regulation of blood pressure; IEA:Ensembl.
DR   GO; GO:0050884; P:neuromuscular process controlling posture; IMP:MGI.
DR   GO; GO:0006809; P:nitric oxide biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0010460; P:positive regulation of heart rate; IEA:Ensembl.
DR   GO; GO:0051000; P:positive regulation of nitric-oxide synthase activity; IDA:UniProtKB.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0051260; P:protein homooligomerization; IDA:UniProtKB.
DR   GO; GO:0042559; P:pteridine-containing compound biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0008217; P:regulation of blood pressure; IMP:UniProtKB.
DR   GO; GO:0014916; P:regulation of lung blood pressure; IEA:Ensembl.
DR   GO; GO:0050999; P:regulation of nitric-oxide synthase activity; TAS:Reactome.
DR   GO; GO:2000121; P:regulation of removal of superoxide radicals; IMP:BHF-UCL.
DR   GO; GO:0034341; P:response to interferon-gamma; IDA:UniProtKB.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IDA:UniProtKB.
DR   GO; GO:0048265; P:response to pain; ISS:UniProtKB.
DR   GO; GO:0034612; P:response to tumor necrosis factor; IDA:UniProtKB.
DR   GO; GO:0006729; P:tetrahydrobiopterin biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0046654; P:tetrahydrofolate biosynthetic process; IEA:InterPro.
DR   GO; GO:0042311; P:vasodilation; IEA:Ensembl.
DR   HAMAP; MF_00223; FolE; 1.
DR   InterPro; IPR001474; GTP_CycHdrlase_I.
DR   InterPro; IPR018234; GTP_CycHdrlase_I_CS.
DR   InterPro; IPR020602; GTP_CycHdrlase_I_dom.
DR   PANTHER; PTHR11109; PTHR11109; 1.
DR   Pfam; PF01227; GTP_cyclohydroI; 1.
DR   TIGRFAMs; TIGR00063; folE; 1.
DR   PROSITE; PS00859; GTP_CYCLOHYDROL_1_1; 1.
DR   PROSITE; PS00860; GTP_CYCLOHYDROL_1_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Allosteric enzyme; Alternative splicing;
KW   Complete proteome; Cytoplasm; Disease mutation; Dystonia; GTP-binding;
KW   Hydrolase; Metal-binding; Nucleotide-binding; Nucleus; Parkinsonism;
KW   Phenylketonuria; Phosphoprotein; Polymorphism; Reference proteome;
KW   Tetrahydrobiopterin biosynthesis; Zinc.
FT   CHAIN         1    250       GTP cyclohydrolase 1.
FT                                /FTId=PRO_0000119478.
FT   METAL       141    141       Zinc. {ECO:0000269|PubMed:11087827}.
FT   METAL       144    144       Zinc. {ECO:0000269|PubMed:11087827}.
FT   METAL       212    212       Zinc. {ECO:0000269|PubMed:11087827}.
FT   MOD_RES      60     60       Phosphoserine.
FT                                {ECO:0000244|PubMed:19690332}.
FT   MOD_RES      81     81       Phosphoserine.
FT                                {ECO:0000269|PubMed:17704208}.
FT   VAR_SEQ     210    250       Missing (in isoform GCH-3).
FT                                {ECO:0000303|PubMed:1520321}.
FT                                /FTId=VSP_001610.
FT   VAR_SEQ     210    233       HMCMVMRGVQKMNSKTVTSTMLGV -> KSNKYNKGLSPLL
FT                                SSCHLFVAILK (in isoform GCH-4).
FT                                {ECO:0000303|PubMed:11284739}.
FT                                /FTId=VSP_001611.
FT   VAR_SEQ     210    213       HMCM -> SAEP (in isoform GCH-2).
FT                                {ECO:0000303|PubMed:1520321,
FT                                ECO:0000303|PubMed:8068008}.
FT                                /FTId=VSP_001612.
FT   VAR_SEQ     214    250       Missing (in isoform GCH-2).
FT                                {ECO:0000303|PubMed:1520321,
FT                                ECO:0000303|PubMed:8068008}.
FT                                /FTId=VSP_001613.
FT   VAR_SEQ     234    250       Missing (in isoform GCH-4).
FT                                {ECO:0000303|PubMed:11284739}.
FT                                /FTId=VSP_001614.
FT   VARIANT      15     15       G -> D (in HGCH-3).
FT                                /FTId=VAR_002632.
FT   VARIANT      23     23       P -> L (in DRD; dbSNP:rs41298432).
FT                                {ECO:0000269|PubMed:9328244}.
FT                                /FTId=VAR_002633.
FT   VARIANT      71     71       L -> Q (in DRD).
FT                                {ECO:0000269|PubMed:9778264}.
FT                                /FTId=VAR_016888.
FT   VARIANT      74     74       A -> V (in DRD).
FT                                {ECO:0000269|PubMed:9778264}.
FT                                /FTId=VAR_016889.
FT   VARIANT      75     75       Y -> C (found in patients with DRD;
FT                                unknown pathological significance).
FT                                /FTId=VAR_072733.
FT   VARIANT      79     79       L -> P (in DRD).
FT                                {ECO:0000269|PubMed:7501255}.
FT                                /FTId=VAR_002634.
FT   VARIANT      83     83       G -> A (in DRD).
FT                                {ECO:0000269|PubMed:10825351,
FT                                ECO:0000269|PubMed:9778264}.
FT                                /FTId=VAR_016890.
FT   VARIANT      88     89       Missing (in DRD).
FT                                {ECO:0000269|PubMed:10825351}.
FT                                /FTId=VAR_016891.
FT   VARIANT      88     88       R -> P (in DRD).
FT                                {ECO:0000269|PubMed:8852666}.
FT                                /FTId=VAR_002635.
FT   VARIANT      88     88       R -> W (in DRD; dbSNP:rs104894433).
FT                                {ECO:0000269|PubMed:7874165}.
FT                                /FTId=VAR_002636.
FT   VARIANT      90     90       G -> V (in DRD).
FT                                {ECO:0000269|PubMed:10076897}.
FT                                /FTId=VAR_016892.
FT   VARIANT      98     98       A -> V.
FT                                /FTId=VAR_072734.
FT   VARIANT     102    102       M -> K (in DRD).
FT                                {ECO:0000269|PubMed:10582612}.
FT                                /FTId=VAR_002637.
FT   VARIANT     102    102       M -> R (in DRD).
FT                                {ECO:0000269|PubMed:10582612}.
FT                                /FTId=VAR_016893.
FT   VARIANT     106    106       T -> I (in DRD).
FT                                {ECO:0000269|PubMed:17101830}.
FT                                /FTId=VAR_054112.
FT   VARIANT     108    108       G -> D (in HPABH4B; intermediate
FT                                phenotype presenting with dystonia and
FT                                motor delay; dbSNP:rs104894435).
FT                                {ECO:0000269|PubMed:9667588}.
FT                                /FTId=VAR_016894.
FT   VARIANT     115    115       D -> N (in DRD).
FT                                {ECO:0000269|PubMed:9328244}.
FT                                /FTId=VAR_016895.
FT   VARIANT     134    134       D -> V (in DRD; dbSNP:rs104894437).
FT                                {ECO:0000269|PubMed:7874165}.
FT                                /FTId=VAR_002638.
FT   VARIANT     135    135       I -> K (in DRD; dbSNP:rs104894441).
FT                                {ECO:0000269|PubMed:10208576}.
FT                                /FTId=VAR_016896.
FT   VARIANT     135    135       I -> T.
FT                                /FTId=VAR_072735.
FT   VARIANT     141    141       C -> R (in DRD).
FT                                {ECO:0000269|PubMed:10582612}.
FT                                /FTId=VAR_016897.
FT   VARIANT     141    141       C -> W (in DRD).
FT                                {ECO:0000269|PubMed:10582612}.
FT                                /FTId=VAR_002639.
FT   VARIANT     144    144       H -> P (in DRD; dbSNP:rs104894440).
FT                                {ECO:0000269|PubMed:8957022}.
FT                                /FTId=VAR_002640.
FT   VARIANT     153    153       H -> P (in DRD).
FT                                {ECO:0000269|PubMed:8852666}.
FT                                /FTId=VAR_002641.
FT   VARIANT     163    163       L -> R (in DRD).
FT                                {ECO:0000269|PubMed:11113234}.
FT                                /FTId=VAR_016898.
FT   VARIANT     176    176       S -> T (in DRD).
FT                                {ECO:0000269|PubMed:10582612}.
FT                                /FTId=VAR_016899.
FT   VARIANT     178    178       R -> S (in DRD).
FT                                {ECO:0000269|PubMed:10582612,
FT                                ECO:0000269|PubMed:10825351,
FT                                ECO:0000269|PubMed:9120469}.
FT                                /FTId=VAR_002642.
FT   VARIANT     180    180       Q -> R (in DRD).
FT                                {ECO:0000269|PubMed:10825351}.
FT                                /FTId=VAR_016900.
FT   VARIANT     184    184       R -> H (in HPABH4B; severe
FT                                hyperphenylalaninemia;
FT                                dbSNP:rs104894445).
FT                                {ECO:0000269|PubMed:7501255}.
FT                                /FTId=VAR_002643.
FT   VARIANT     186    186       T -> K (in DRD).
FT                                {ECO:0000269|PubMed:10582612}.
FT                                /FTId=VAR_002644.
FT   VARIANT     191    191       V -> I (in DRD; dbSNP:rs762208304).
FT                                {ECO:0000269|PubMed:9778264}.
FT                                /FTId=VAR_016901.
FT   VARIANT     199    199       P -> L (in DRD).
FT                                {ECO:0000269|PubMed:10825351}.
FT                                /FTId=VAR_016902.
FT   VARIANT     201    201       G -> E (in DRD; dbSNP:rs104894438).
FT                                {ECO:0000269|PubMed:10825351,
FT                                ECO:0000269|PubMed:7874165}.
FT                                /FTId=VAR_002645.
FT   VARIANT     203    203       G -> R (in DRD).
FT                                {ECO:0000269|PubMed:8852666}.
FT                                /FTId=VAR_002646.
FT   VARIANT     211    211       M -> I (in HPABH4B; severe
FT                                hyperphenylalaninemia;
FT                                dbSNP:rs104894443).
FT                                {ECO:0000269|PubMed:7501255}.
FT                                /FTId=VAR_002647.
FT   VARIANT     211    211       M -> V (in DRD).
FT                                {ECO:0000269|PubMed:9778264}.
FT                                /FTId=VAR_016903.
FT   VARIANT     213    213       M -> V (in DRD).
FT                                {ECO:0000269|PubMed:11113234}.
FT                                /FTId=VAR_016904.
FT   VARIANT     221    221       M -> T (in HPABH4B; intermediate
FT                                phenotype presenting with dystonia and
FT                                motor delay; compound heterozygote for an
FT                                additional deletion; dbSNP:rs104894434).
FT                                {ECO:0000269|PubMed:9667588}.
FT                                /FTId=VAR_016905.
FT   VARIANT     224    224       K -> R (in HPABH4B and DRD; phenotype
FT                                presenting with dystonia and myoclonus;
FT                                dbSNP:rs41298442).
FT                                {ECO:0000269|PubMed:12391354,
FT                                ECO:0000269|PubMed:8852666,
FT                                ECO:0000269|PubMed:9667588}.
FT                                /FTId=VAR_002648.
FT   VARIANT     234    234       F -> S (in DRD).
FT                                {ECO:0000269|PubMed:8852666}.
FT                                /FTId=VAR_002649.
FT   VARIANT     241    241       R -> W (in DRD).
FT                                {ECO:0000269|PubMed:9778264}.
FT                                /FTId=VAR_016906.
FT   VARIANT     249    249       R -> S (in DRD; dbSNP:rs104894442).
FT                                {ECO:0000269|PubMed:10987649}.
FT                                /FTId=VAR_016907.
FT   CONFLICT     11     11       E -> G (in Ref. 4; AAD38866).
FT                                {ECO:0000305}.
FT   CONFLICT    206    206       V -> I (in Ref. 9; CAA78908).
FT                                {ECO:0000305}.
FT   HELIX        61     81       {ECO:0000244|PDB:1FB1}.
FT   HELIX        91     93       {ECO:0000244|PDB:1FB1}.
FT   HELIX        94    102       {ECO:0000244|PDB:1FB1}.
FT   TURN        103    106       {ECO:0000244|PDB:1FB1}.
FT   HELIX       108    110       {ECO:0000244|PDB:1FB1}.
FT   TURN        113    115       {ECO:0000244|PDB:1FB1}.
FT   STRAND      130    141       {ECO:0000244|PDB:1FB1}.
FT   TURN        142    144       {ECO:0000244|PDB:1FB1}.
FT   STRAND      147    156       {ECO:0000244|PDB:1FB1}.
FT   HELIX       165    176       {ECO:0000244|PDB:1FB1}.
FT   STRAND      177    180       {ECO:0000244|PDB:1FB1}.
FT   HELIX       182    197       {ECO:0000244|PDB:1FB1}.
FT   STRAND      202    210       {ECO:0000244|PDB:1FB1}.
FT   HELIX       211    214       {ECO:0000244|PDB:1FB1}.
FT   TURN        215    217       {ECO:0000244|PDB:1FB1}.
FT   STRAND      224    230       {ECO:0000244|PDB:1FB1}.
FT   HELIX       233    236       {ECO:0000244|PDB:1FB1}.
FT   HELIX       238    248       {ECO:0000244|PDB:1FB1}.
SQ   SEQUENCE   250 AA;  27903 MW;  B8A0CB344C598B9A CRC64;
     MEKGPVRAPA EKPRGARCSN GFPERDPPRP GPSRPAEKPP RPEAKSAQPA DGWKGERPRS
     EEDNELNLPN LAAAYSSILS SLGENPQRQG LLKTPWRAAS AMQFFTKGYQ ETISDVLNDA
     IFDEDHDEMV IVKDIDMFSM CEHHLVPFVG KVHIGYLPNK QVLGLSKLAR IVEIYSRRLQ
     VQERLTKQIA VAITEALRPA GVGVVVEATH MCMVMRGVQK MNSKTVTSTM LGVFREDPKT
     REEFLTLIRS
//
